Participants 97 205 5
patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors:
Participants 428 540 4
patients with rheumatoid arthritis (RA) who had an inadequate response to tumor necrosis factor (TNF) inhibitors
Participants 550 678 3
Patients in REFLEX were originally randomized to placebo (PBO) + methotrexate (MTX; PBO-randomized) or RTX + MTX (RTX-randomized
Participants 1232 1279 6
A total of 480 patients received â‰¥ 1 RTX cour
